Capabilities

End-to-end clinical development, powered by a disciplined platform model.

Thelamux combines deep clinical development capabilities with a structured platform approach to source, advance, and realize value from clinical-stage assets.

Platform Capabilities

Sourcing, structuring, and capital deployment.

The Thelamux platform engine — disciplined asset selection and capital allocation across the portfolio.

Asset Sourcing

· Identification of clinical-stage opportunities aligned with platform strategy
· Selective focus on assets with clear scientific rationale and inflection points

In-Licensing

· Deal structuring aligned with platform economics
· Flexible ownership models
· Capital-efficient acquisition strategies

Capital Allocation

· Milestone-gated deployment
· Alignment of capital with value inflection points
· Portfolio-level prioritization

BD & Partnerships

· Out-licensing and partnership readiness
· Strategic positioning of assets
· Alignment with potential commercial partners

Discovery Capabilities Telaplex — Discovery

Originate novel compounds, capital-efficiently.

The Telaplex discovery engine is designed to originate novel compounds through hypothesis-driven design and translational science, executed through external research infrastructure.

Compound Generation

· Hypothesis-driven design and target validation
· Novel scaffold development aligned with platform strategy

Translational Science

· Biomarker and endpoint framework
· Preclinical-to-clinical translation strategy

External Research Infrastructure

· Academic and CRO research networks
· Capital-efficient access to specialized capabilities

Preclinical Validation

· In vitro and in vivo efficacy assessment
· IND-enabling readiness through external partnerships

Development Capabilities Telanode — Development

Execution across the clinical lifecycle.

The Telanode development engine advances assets through milestone-driven clinical execution, regulatory strategy, clinical operations, and commercial readiness — with clear ownership and disciplined capital deployment.

Clinical Development

Operations

Regulatory

Commercialization

Clinical Development (Phase 1–3)

· Trial design and protocol development
· Site selection and investigator engagement
· Execution across oncology, hematology, and high-science indications
· Adaptive decision-making based on emerging data

Clinical Operations

· CRO and vendor management
· Trial execution and oversight
· Data monitoring and operational workflows

Regulatory Strategy & FDA Engagement

· IND submissions and regulatory filings
· FDA and global regulatory interactions
· Alignment of regulatory strategy with development milestones

Commercialization

· Positioning aligned to clinical outcomes
· Preparation for partnership, licensing, or continuation
· Alignment of development strategy with commercial potential

End-to-end clinical development, powered by a disciplined platform model.

Sourcing, structuring, and capital deployment.

Originate novel compounds, capital-efficiently.

Execution across the clinical lifecycle.

Want to see how this applies to a specific Telanode?